Merck shares fall 9% despite earnings beat, strong demand for top drugs like Keytruda

[ad_1] The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb.…

Lost in the market’s sharp rotation out of tech stocks is a really bullish call on major banks

[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable…

Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs

[ad_1] Kena Betancur | Corbis News | Getty Images Pfizer on Tuesday reported second-quarter revenue and adjusted…

Neuralink rival Synchron’s brain implant now lets people control Apple’s Vision Pro with their minds

[ad_1] Mark uses the Vision Pro with his BCI Courtesy of Synchron Neurotech startup Synchron on…

Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says

[ad_1] A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter…

We’re encouraged by Abbott stock trading but discouraged by moves in Honeywell

[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable…

Here are JPMorgan’s top drug stock picks into earnings

[ad_1] JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue…

Jim Cramer’s advice on Abbott Labs stock after a nearly $500 million baby formula verdict

[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at…

We’re making a flurry of moves: trimming 2 stocks and buying 2 others that have lagged

[ad_1] We’re making four trades Monday morning. Shortly after the opening bell, we will be selling…

FDA approves new blood test to screen for colon cancer

[ad_1] The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to…

These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments

[ad_1] The lucrative market for weight loss drugs won’t stay a duopoly forever. With billions at…

Dexcom shares plunge more than 40% for worst day on record

[ad_1] Dexcom shares sank more than 40% on Friday, their steepest decline ever, after the diabetes…

Dexcom shares plummet almost 40% after company misses on revenue, lowers guidance

[ad_1] The Dexcom logo is seen on a smartphone screen and in the background. Pavlo Gonchar…

An ugly earnings report from a competitor is good news for Abbott Labs

[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at…

Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs 

[ad_1] The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on…

Newseum Global